News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
lol
the call is being hosted by Allele Capital and they have Nasdaq Companies and Private Companies on their "engagements" page. Allele Capital has raised money for a few of them. https://www.allelecapital.com/engagements
PPCB is the only OTC stock they have worked with (that I can see)!
nice!!! thanks!!!!!!
News!!! Conference Call on March 28th on the compassionate use study results!!! https://www.otcmarkets.com/stock/PPCB/news/story?e&id=2774171
on a side note, Share structure updated approximately 13 million shares added to O/S from January 9th to February 9th:
Outstanding Shares: 52,144,948 02/09/2024
Restricted Shares: 727,859 02/09/2024
Unrestricted Shares: 51,417,089 02/09/2024
Buying today, hopefully I can finally catch a run with PPCB!!!!!!
|
Followers
|
407
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
48340
|
|
Created
|
05/18/14
|
Type
|
Free
|
| Moderators | |||
This section maintained by INV4
Offering New Hope to Cancer Patients and Their Caregivers
| About Propanc Biopharma, Inc. The Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer. A Long-Term Therapy Based on a Pancreatic Proenzyme Formulation Developing Long-Term Therapy for the Treatment of Solid Tumors Technology Based on Pancreatic Proenzyme Therapy Treatments that Inhibit Tumor Growth and Metastasis Our Lead Product: PRP Technology Based on Pancreatic Enzyme Therapy More than one hundred years ago, Professor John Beard first proposed that the pancreatic enzymes represent the body’s primary defense against cancer and would be useful as a cancer treatment. Since then, several scientists have endorsed Beard´s hypothesis with encouraging data from patient treatment. |
Click here for the video (with sound)
====================== PPCB SECURITY DETAILS ======================
Share Structure
Market Cap | 1,652,679 | 02/27/2023
Authorized Shares | 10,000,000,000 | 02/13/2023
Outstanding Shares | 1,836,310,391 | 02/13/2023
Restricted | 194,354,827 | 02/13/2023
Unrestricted | 1,641,955,564 | 02/13/2023
Held at DTC | 1,641,916,456 | 02/13/2023
| Board of Directors James Nathanielsz has served as a director and Chief Executive Officer of our company since October 2007. From July 2006 until October 2007, Mr. Nathanielsz served as the New Products Manager of Biota Holdings Limited, an anti-infective drug development company in Australia. Mr. Nathanielsz was selected as a director because he is the Co-Founder of Propanc and for his experience in R&D and manufacturing and distribution. Mr. Nathanielsz holds a B.App.Sci in Biochemistry/Applied Chemistry and an M.E.I. from Swinburne University of Technology in Melbourne, Australia. ============== Dr. Julian Kenyon founded our company and was appointed as a director on February 12, 2008. Since 2000, Dr. Kenyon has served as an integrated medical physician and Medical Director of the Dove Clinic for Integrated Medicine in Winchester and London. He was the Founder-Chairman of the British Medical Acupuncture Society in 1980 and Co-Founder of the Centre for the Study of Complementary Medicine in Southampton and London. Dr. Kenyon was selected as a director because he is the Co-Founder of the Australian subsidiary and the business is based on his initial work at the Dove Clinic. Dr. Kenyon holds an M.B.Ch.B. and M.D. from the University of Liverpool Since 1972, he was appointed a Primary Fellow of the Royal College of Surgeons, Edinburgh. ============== Mr Zelinger is a Certified Practicing Accountant with 45 years of experience in tax, auditing, finance, investment and management consulting. Mr Zelinger also has significant expertise in property management and import/export businesses. Mr Zelinger commenced his career as an accountant at L.M. Stanton & Partners - Chartered Accountants, subsequently joining Caston Pty Ltd in 1980, a steel manufacturer as Chief Financial Officer, and Company Director, until 1983. Since the mid-1980’s until current date, Mr Zelinger serves as Director in several private investment companies in a range of businesses including property portfolio manager of commercial real estate, import/export businesses and a range of commercial and financial investment companies. Since 1980, Mr Zelinger also operates as a sole practitioner in accountancy and tax consulting. In 1973, Mr Zelinger graduated in Accounting and admitted as a Fellow of RMIT University in Business. He has been a Certified Practicing Accountant since 1984. Mr. Zelinger is a shareholder of Propanc Biopharma Inc. since 2010. ======================================================================== Company Info Industry Classifications |
